 Connection
Paul Bunn to Pemetrexed
This is a "connection" page, showing publications Paul Bunn has written about Pemetrexed.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.738 |
|
|
|
-
Paz-Ares LG, Zimmermann A, Ciuleanu T, Bunn PA, Antonio BS, Denne J, Iturria N, John W, Scagliotti GV. Meta-analysis examining impact of age on overall survival with pemetrexed for the treatment of advanced non-squamous non-small cell lung cancer. Lung Cancer. 2017 02; 104:45-51.
Score: 0.142
-
Weiss GJ, Rosell R, Fossella F, Perry M, Stahel R, Barata F, Nguyen B, Paul S, McAndrews P, Hanna N, Kelly K, Bunn PA. The impact of induction chemotherapy on the outcome of second-line therapy with pemetrexed or docetaxel in patients with advanced non-small-cell lung cancer. Ann Oncol. 2007 Mar; 18(3):453-60.
Score: 0.072
-
Weiss GJ, Zeng C, Kelly K, Tran ZV, Bunn PA. Single-institution experience with pemetrexed and bevacizumab as salvage therapy in advanced non-small-cell lung cancer. Clin Lung Cancer. 2007 Mar; 8(5):335-8.
Score: 0.072
-
Solomon B, Bunn PA. Clinical activity of pemetrexed: a multitargeted antifolate anticancer agent. Future Oncol. 2005 Dec; 1(6):733-46.
Score: 0.066
-
Bunn P. New investigative regimens and cytotoxic agents in thoracic cancers: gemcitabine and pemetrexed. Oncology (Williston Park). 2004 Jul; 18(8 Suppl 5):5-11.
Score: 0.060
-
Hanna N, Shepherd FA, Fossella FV, Pereira JR, De Marinis F, von Pawel J, Gatzemeier U, Tsao TC, Pless M, Muller T, Lim HL, Desch C, Szondy K, Gervais R, Manegold C, Paul S, Paoletti P, Einhorn L, Bunn PA. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol. 2004 May 01; 22(9):1589-97.
Score: 0.059
-
Niyikiza C, Hanauske AR, Rusthoven JJ, Calvert AH, Allen R, Paoletti P, Bunn PA. Pemetrexed safety and dosing strategy. Semin Oncol. 2002 Dec; 29(6 Suppl 18):24-9.
Score: 0.054
-
Bunn PA. Incorporation of pemetrexed (Alimta) into the treatment of non-small cell lung cancer (thoracic tumors). Semin Oncol. 2002 Jun; 29(3 Suppl 9):17-22.
Score: 0.052
-
Postmus PE, Bunn PA. Pemetrexed as a single agent in the therapy of advanced lung cancer. Semin Oncol. 2002 Apr; 29(2 Suppl 5):17-22.
Score: 0.051
-
Calvert H, Bunn PA. Future directions in the development of pemetrexed. Semin Oncol. 2002 Apr; 29(2 Suppl 5):54-61.
Score: 0.051
-
Shepherd FA, Bunn PA, Paz-Ares L. Lung cancer in 2013: state of the art therapy for metastatic disease. Am Soc Clin Oncol Educ Book. 2013; 339-46.
Score: 0.027
-
Weiss GJ, Langer C, Rosell R, Hanna N, Shepherd F, Einhorn LH, Nguyen B, Paul S, McAndrews P, Bunn PA, Kelly K. Elderly patients benefit from second-line cytotoxic chemotherapy: a subset analysis of a randomized phase III trial of pemetrexed compared with docetaxel in patients with previously treated advanced non-small-cell lung cancer. J Clin Oncol. 2006 Sep 20; 24(27):4405-11.
Score: 0.017
-
Monnerat C, Le Chevalier T, Kelly K, Obasaju CK, Brahmer J, Novello S, Nakamura T, Liepa AM, Bozec L, Bunn PA, Ettinger DS. Phase II study of pemetrexed-gemcitabine combination in patients with advanced-stage non-small cell lung cancer. Clin Cancer Res. 2004 Aug 15; 10(16):5439-46.
Score: 0.015
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|